MSA
CLDX icon

Marino Stram & Associates’s Celldex Therapeutics CLDX Stock Holding History

Marino Stram & Associates’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-11
Closed – – 162
2019
Q1 		$0 Buy
+11
New +$58 ﹤0.01% 631
2018
Q4 		– Sell
-11
Closed – – 625
2018
Q3 		$0 Hold
11
– – ﹤0.01% 486
2018
Q2 		$0 Hold
11
– – ﹤0.01% 485
2018
Q1 		$0 Hold
11
– – ﹤0.01% 464
2017
Q4 		$0 Buy
+11
New +$471 ﹤0.01% 462

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marino Stram & Associates's CLDX Position: Q2 2019 in Review

Marino Stram & Associates sold out of Celldex Therapeutics (CLDX) in Q2 2019, closing a stake of 11 shares.

Marino Stram & Associates first reported a position in CLDX in Q4 2017 and held it in 5 quarters. The position peaked at $0 in Q1 2019. 51 funds tracked by Wall St. Rank hold CLDX as of Q2 2019.

  • Marino Stram & Associates reported no remaining Celldex Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Marino Stram & Associates sold 11 Celldex Therapeutics shares in Q2 2019.
  • Marino Stram & Associates first reported a position in Celldex Therapeutics in Q4 2017 and held it in 5 quarters.
  • Marino Stram & Associates's Celldex Therapeutics position peaked at $0 in Q1 2019.
  • 51 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2019.

Based on Marino Stram & Associates's 13F filing for Q2 2019, filed 19 Jul 2019.